Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€453.00

€453.00

-0.010%
-0.05
-0.010%
€545.00
 
16:55 / Tradegate WKN: 882807 / Symbol: VRTX / Name: Vertex / Stock / Biotechnology & Medical Research / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Vertex Pharmaceuticals Inc. Stock

There is nearly no change for the Vertex Pharmaceuticals Inc. stock today. Compared to yesterday it only changed by -€0.050.
With 71 Buy predictions and 2 Sell predictions Vertex Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 545 € shows a positive potential of 20.31% compared to the current price of 453.0 € for Vertex Pharmaceuticals Inc..
For the coming years our community has positive and negative things to say abot the Vertex Pharmaceuticals Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.

Pros and Cons of Vertex Pharmaceuticals Inc. in the next few years

Pros
?
C******** o* t** e**********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Vertex Pharmaceuticals Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Vertex Pharmaceuticals Inc. -0.010% 3.768% 1.060% 45.886% 21.902% 171.645% 191.238%
Exact Sciences 3.860% 3.213% 5.212% -52.310% -39.756% -59.022% -59.730%
Incyte Corp. 0.940% 7.539% 3.502% 0.420% 1.057% -16.971% -20.527%
Regeneron Pharmaceuticals Inc. 1.050% 5.093% 5.764% 52.663% 24.715% 103.499% 287.004%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-29

Vertex Pharmaceuticals Inc (VRTX) has been growing consistently in the Biotechnology & Medical Research industry in recent years, as indicated by its financial statements. The company's financials, from its balance sheets to its income and cash flow statements, exhibit a strong growth in its assets, revenues, and profits.

Vertex has shown significant growth in total assets, as evidenced by a consistent increase from almost $11.75 billion in 2020 to over $18.15 billion in 2022. This growth highlights the company's strong financial position, enabling it to capitalize on investment opportunities and fuel further expansion.

The total revenue Vertex generated also increased from over $6.2 billion in 2020 to nearly $8.9 billion in 2022. The steady rise in sales is a positive sign for investors and points to the company's successful execution of its growth strategy.

Comments

Prediction Buy
Perf. (%) 0.00%
Target price 545.000
Change
Ends at 12.07.25

Vertex Pharmaceuticals has been on a roll lately, consistently outpacing the overall stock market. Their upcoming vanza triple therapy for cystic fibrosis seems very promising, with the FDA already granting it priority review. This could be a significant new growth driver for the company. The analysts at Redburn Atlantic are also bullish on Vertex, initiating coverage with a 'buy' rating and a $545 target price. Given the company's strong pipeline, innovative therapies, and positive momentum, I believe Vertex is a solid investment opportunity that's worth considering.
Show more

Prediction Buy
Perf. (%) 0.00%
Target price 545.000
Change
Ends at 12.07.25

Vertex Pharmaceuticals is a solid biotech stock that has consistently outperformed the broader market. The company's pipeline of cystic fibrosis treatments is particularly promising, with the recent FDA acceptance of its Vanza triple therapy application being a significant milestone. Analysts are bullish on the stock, with Redburn Atlantic initiating coverage with a 'buy' rating and a target price of $545, representing a potential upside of over 20% from the current level. While the stock is not cheap, trading at around 30 times forward earnings, the long-term growth potential appears compelling, given the unmet need in the cystic fibrosis market. Think of it like a luxury sports car - it may come with a hefty price tag, but the performance and prestige make it worth considering for your portfolio.
Show more

Prediction Buy
Perf. (%) 0.25%
Target price 545.000
Change
Ends at 12.07.25

Vertex Pharmaceuticals is a biotech powerhouse that continues to outperform the broader market. With its promising pipeline and strong financial performance, I believe the company is well-positioned for further growth. The FDA's acceptance of the NDA for the vanza triple therapy is a significant milestone, and I'm excited to see how this new treatment option could benefit patients with cystic fibrosis. Vertex's track record of innovation and its ability to consistently deliver results make it an attractive investment opportunity in my opinion. While there are always risks involved in the pharmaceutical industry, Vertex's diversified product portfolio and robust R&D efforts suggest to me that the company is a solid long-term bet. It's like a well-oiled machine, consistently cranking out new and improved treatments that make a real difference in people's lives.
Show more

News

Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).: https://g.foolcdn.com/editorial/images/782488/gettyimages-1357572936.jpg
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).

Vertex Pharmaceuticals (NASDAQ: VRTX) transformed the world of cystic fibrosis (CF) treatment when it launched its first product for the disease 12 years ago. Since then, it's built a CF treatment

1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/782105/physician-talking-to-patient.jpg
1 Stock That Increased 10,000% in 33 Years to Buy and Hold Forever

Investing in equity markets is a reliable, wealth-growing strategy. In the past 33 years, the S&P 500's average annual return is about 10.6%. It's hard to find a return much better than that

Did Vertex Pharmaceuticals Just Invent the Next Ozempic?: https://g.foolcdn.com/editorial/images/782327/healthcare-lab-treatment-research-scientist.jpg
Did Vertex Pharmaceuticals Just Invent the Next Ozempic?

With Vertex Pharmaceuticals (NASDAQ: VRTX) announcing on June 21 that its therapy VX-880 helped nearly all of the patients with diabetes in a clinical trial to reduce or eliminate their need for